-
2023-510515-19-00
5
2020-11-27
Higher-risk-myelodysplastic syndromes
-
2024-519007-10-00
10
2020-10-22
Locally advanced stage II/III rectal cancer
-
2024-518623-30-00
6
2020-10-01
metastatic castration resistant prostate cancer without mutations of B
-
2023-510433-29-00
5
2020-09-24
Favorable-intermediate-risk Acute Myeloid Leukemia
-
2023-510516-39-00
4
2019-10-30
Acute B-cell Lymphoblastic Leukemia with minimal residual positive dis
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-520108-25-00
4
2025-11-05
Non-small cell lung cancer (NSCLC)
-
2024-516909-23-00
4
2025-10-28
Locally Advanced Resectable Gastroesophageal Adenocarcinoma
-
2025-520809-12-00
10
2025-10-16
Diabetic Macular Edema
-
2024-519773-19-00
5
2025-07-31
Gastroesophageal Junction Adenocarcinoma
-
2024-515907-20-00
9
2025-05-23
Primary biliary cholangitis (PBC)
-
2024-512946-41-00
5
2025-03-05
Menstrual Migraine
-
2023-505394-32-00
5
2025-02-06
chronic graft versus host disease
-
2024-520121-36-00
4
2025-01-28
The following categories of HCL patients needing anti-leukemic treatme
-
2024-518842-26-00
4
2025-01-21
Cancer in the stomach or in the junction between the stomach and the o
-
2024-510944-30-00
10
2024-11-22
Diabetic Macular Edema
-
2024-511482-11-00
5
2024-11-20
Dry Age-Related Macular Degeneration (Dry AMD)
-
2024-514343-29-00
5
2024-11-19
multiple sclerosis
-
2023-504040-34-01
5
2024-11-12
Crohn’s Disease
-
2024-513540-29-00
5
2024-11-07
Breast Cancer
-
2024-511627-34-00
4
2024-10-17
Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)
-
2024-513271-41-00
4
2024-09-16
colorectal metastatic cancer
-
2023-508219-21-00
5
2024-09-12
BTC - Biliary Tract Cancer